Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
Focal segmental glomerulosclerosis (FSGS) is a kidney disorder characterized by scarring in portions of selected glomeruli, often causing proteinuria and progressive renal dysfunction. As per the Rare Disease Advisor FSGS contributes to about 40% of adult and 20% of pediatric nephrotic syndrome cases. The FSGS drug pipeline is expanding beyond corticosteroids and calcineurin inhibitors toward targeted therapies addressing podocyte injury, immune pathways, and proteinuria. According to the focal segmental glomerulosclerosis (FSGS) pipeline analysis by Expert Market Research, unmet treatment needs and kidney disease burden are supporting continued clinical development.
-
Major companies involved in focal segmental glomerulosclerosis (FSGS) pipeline analysis include Boehringer Ingelheim, Dimerix Bioscience Pty Ltd., and others.
-
Leading drugs currently in the pipeline include BI 764198, DMX-200, and others.
-
Late-stage therapies, novel mechanisms, and biomarker-driven patient selection are expected to accelerate development, while targeted treatments and improved clinical differentiation strengthen therapeutic competition.
Report Coverage
The Focal Segmental Glomerulosclerosis (FSGS) Pipeline Analysis Report by Expert Market Research gives comprehensive insights into focal segmental glomerulosclerosis (FSGS) therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for focal segmental glomerulosclerosis (FSGS). The focal segmental glomerulosclerosis (FSGS) report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The focal segmental glomerulosclerosis (FSGS) Pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with focal segmental glomerulosclerosis (FSGS) treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to focal segmental glomerulosclerosis (FSGS).
Read more about this report - Request a Free Sample
Focal Segmental Glomerulosclerosis (FSGS) Pipeline Outlook
Focal segmental glomerulosclerosis (FSGS) is a rare kidney disease characterized by scarring in portions of the glomeruli, the kidney’s filtering units. Injury to these filters disrupts normal filtration, allowing excessive proteinuria and other substances to enter the urine. Progressive damage can reduce kidney function and potentially lead to kidney failure.
Focal segmental glomerulosclerosis (FSGS) treatment aims to reduce proteinuria, control blood pressure, and preserve kidney function. Management may include corticosteroids, immunosuppressive therapies, renin-angiotensin system inhibitors, supportive care, and targeted therapies for appropriate patients. In April 2026, the U.S. Food and Drug Administration (FDA) approved Filspari (sparsentan) for patients aged eight years and older with Focal Segmental Glomerulosclerosis (FSGS) without nephrotic syndrome, marking the first FDA-approved treatment for this population and strengthening the FSGS drug pipeline.
Focal Segmental Glomerulosclerosis (FSGS) Epidemiology
FSGS represents a significant disease burden, supporting continued development of targeted therapies in the FSGS drug pipeline. According to Rare Disease Advisor, FSGS accounts for approximately 20% of nephrotic syndrome cases in children and nearly 40% in adults. A 2024 cross-sectional study covering 2010–2021 found that primary FSGS represented 16.6% of biopsy-confirmed cases. According to Mascarenhas-Melo et al. (2025), FSGS accounts for 10%–20% of adult glomerulopathies diagnosed by kidney biopsy in Europe, while the United Kingdom recorded approximately 26,000 newly diagnosed cases in 2022. These epidemiological trends reinforce the need for continued FSGS treatment development.
Focal Segmental Glomerulosclerosis (FSGS) – Pipeline Therapeutic Assessment
This section of the report covers the analysis of focal segmental glomerulosclerosis (FSGS) drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase 1)
- Preclinical and Discovery Stage Products
By Drug Class
The focal segmental glomerulosclerosis (FSGS) pipeline analysis report covers 50+ drug analyses based on drug classes:
- Small Molecules
- Monoclonal Antibodies
- Peptides
- Antisense Oligonucleotides
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration:
- Oral
- Parenteral
- Others
Focal Segmental Glomerulosclerosis (FSGS) Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to Expert Market Research analysis, phase II with 53%, covers a major share of the total focal segmental glomerulosclerosis (FSGS) clinical trials, with a strong focus on advancing investigational therapies toward clinical validation, supporting continued pipeline expansion. Phase III at 26% reflects increasing progression toward advanced-stage development and potential commercialization. Phase I with 16% supports early therapeutic innovation, while phase IV at 5% contributes to post-approval evidence generation and treatment optimization.
Focal Segmental Glomerulosclerosis (FSGS) Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the focal segmental glomerulosclerosis (FSGS) pipeline analysis include small molecules, monoclonal antibodies, peptides, and antisense oligonucleotides. The focal segmental glomerulosclerosis (FSGS) report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for focal segmental glomerulosclerosis (FSGS). Endothelin receptor antagonist therapies are emerging as an important drug class in the focal segmental glomerulosclerosis pipeline. For instance, sparsentan (FILSPARI), a dual endothelin A and angiotensin II receptor antagonist, targets pathways associated with glomerular stress, inflammation, and scarring. In April 2026, the U.S. Food and Drug Administration approved sparsentan to reduce proteinuria in patients with FSGS without nephrotic syndrome.
Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials – Key Players
The EMR report for the focal segmental glomerulosclerosis (FSGS) pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed focal segmental glomerulosclerosis (FSGS) therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in focal segmental glomerulosclerosis (FSGS) clinical trials:
- Boehringer Ingelheim
- Dimerix Bioscience Pty Ltd.
- Bio-Thera Solutions
- Apellis Pharmaceuticals, Inc.
- Everest Medicines (China) Co., Ltd.
- Akebia Therapeutics
- Sanofi
- Travere Therapeutics, Inc.
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Walden Biosciences
Focal Segmental Glomerulosclerosis (FSGS) – Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for focal segmental glomerulosclerosis (FSGS). It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of focal segmental glomerulosclerosis (FSGS) drug candidates.
Drug: BI 764198
BI 764198 (apecotrep), sponsored and developed by Boehringer Ingelheim, is an investigational, oral, once-daily, non-immunosuppressive, selective TRPC6 inhibitor. The drug is being evaluated in a Phase III study to determine whether it can reduce proteinuria and slow disease progression in adults and adolescents with primary or TRPC6-related genetic FSGS. By inhibiting overactivated TRPC6 channels, BI 764198 is intended to limit excessive calcium entry into podocytes and protect these kidney filtration cells. Participants are taking tablets for up to 104 weeks alongside standard FSGS medication. The study is estimated to be completed in January 2029.
Drug: DMX-200
DMX-200 (repagermanium), sponsored by Dimerix Bioscience Pty Ltd, is an investigational C-C chemokine receptor type 2 (CCR2) inhibitor being evaluated in the Phase 3 ACTION3 study for FSGS. The study is examining whether DMX-200, administered alongside an angiotensin II receptor blocker (ARB), will reduce proteinuria and slow kidney function decline by inhibiting monocyte recruitment associated with chronic inflammation. The drug is being administered orally as 120 mg capsules twice daily. The study will include adults and adolescents aged 12–17 years and is expected to be completed in December 2029, followed by an open-label extension of up to two additional years.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
Key Questions Answered in the Focal Segmental Glomerulosclerosis (FSGS) Pipeline Insight Report
- Which companies/institutions are leading the focal segmental glomerulosclerosis (FSGS) drug development?
- Which company is leading the focal segmental glomerulosclerosis (FSGS) pipeline development activities?
- What is the current focal segmental glomerulosclerosis (FSGS) commercial assessment?
- What are the opportunities and challenges present in the focal segmental glomerulosclerosis (FSGS) pipeline landscape?
- What is the efficacy and safety profile of focal segmental glomerulosclerosis (FSGS) pipeline drugs?
- Which company is conducting major trials for focal segmental glomerulosclerosis (FSGS) drugs?
- Which companies/institutions are involved in focal segmental glomerulosclerosis (FSGS) collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in focal segmental glomerulosclerosis (FSGS)?
Reasons To Buy This Report
The focal segmental glomerulosclerosis (FSGS) pipeline analysis report provides a strategic overview of the latest and future landscape of treatments for focal segmental glomerulosclerosis (FSGS). It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into focal segmental glomerulosclerosis (FSGS) collaborations, regulatory environments, and potential growth opportunities.
Related Reports
Pricing Plans
Upto 15% Off
USD
-
$1999 $1799
-
$3099 $2789
-
$4599 $3909
-
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
